Special Issue "Vaccines for Zoonotic Viral Infectious Diseases"
Deadline for manuscript submissions: 31 January 2024 | Viewed by 1192
Interests: SARS-CoV-2; DNA vaccine; emerging viral diseases; subunit vaccine; infectious disease epidemiology
Interests: emerging viruses; vaccine; vaccine platform; animal models; immune response
Currently, emerging and zoonotic viral infectious diseases are considered a serious threat to public health. Some zoonotic viral illnesses, such as Coronavirus (SARS, MERS, and most recently, SARS-CoV-2), influenza, Nipah virus, Hendra virus, Ebola virus, and other vector-borne viruses, have endangered human and animal health and resulted in significant financial loss. Over the past 100 years, vaccinations are definitely the most effective preventive tool against infectious diseases and represent one of the most important achievements in medicine. Although this is significant, this number becomes proportionately tiny when compared to the total number of diseases that currently affect both humans and animals worldwide. This illustrates gaps in knowledge on particular pathogens, immunopathology, and the nuanced interaction between pathogen and host. As a result, although receiving a lot of attention, several diseases that are widespread around the world still lack a reliable vaccination or even a pre-clinical or clinical study that is actively being conducted. This Special Issue invites all types of manuscripts, including reviews, research articles, and short communications. The topics may include (but are not restricted to) antigen design, new effective adjuvants and delivery techniques, cross-protection between various genotypes/serotypes, methods and means for evaluating vaccine efficacy and safety, and the immunogen design and investigation for universal vaccines.
We look forward to receiving your contributions.
Dr. Zhuo Ha
Dr. Lili Zhao
Dr. Hao Liu
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- emerging viruses
- vaccine efficacy
- immunogen design